OTC: USAQ

Core
platform capabilities include:

●
Digital health assessments administered prior to or outside
of office visits

●
Adaptive assessment logic that adjusts based on patient responses

●
Identification of clinical risk factors and patient-reported
interest in receiving care

●
Imminent risk alerts (e.g., suicide risk) with patient and
provider next-step instructions

●
Automated generation of patient-facing and provider-facing
reports

●
Delivery of provider reports into the practice’s electronic
health record (EHR)

●
Ongoing digital follow-up, education, and periodic patient
check-ins

●
Support for non-face-to-face and care management workflows

The
platform is designed to be modular and extensible, allowing new clinical domains and assessment variables to be added over time.

Patient
Flow and Care Model

QHSLab’s
care model is structured around a repeatable patient journey that may be applied across large patient populations. The platform facilitates
the delivery of health care over an extended period focusing on the full spectrum of a patient’s health, not just isolated conditions.

Patients
typically receive a digital health assessment prior to a scheduled office visit or as part of routine care. The assessment adapts in
real time based on patient responses and is designed to identify potential clinical or lifestyle-related risk areas, as well as patient
interest in receiving assistance.

Upon
completion, the platform automatically scores the assessment and generates structured reports for both the patient and the provider.
The provider report is designed for clinical use and is delivered into the practice’s electronic health records, enabling the physician
to review relevant findings prior to or during the patient’s encounter.

Following
the office visit, patients may receive ongoing digital engagement, including educational content, self-management materials, asynchronous
communication, and periodic check-ins. For appropriate patients, additional non-face-to-face monitoring or care management activities
may occur over time. In short, the platform enables a standardized workflow to capture → stratify → escalate → document
→ dashboard → reimburse across primary care populations.

3

Revenue
Model

Our
revenue model consists of recurring subscription and service fees charged to participating medical practices on a per-patient, per-month
basis. Fees are generally structured as flat amounts tied to platform access, digital care workflows, and support services.

We
do not bill patients or payers directly. Participating practices are responsible for billing applicable payers for clinical services
rendered using the platform, including digital assessments, asynchronous interactions, and care management services, subject to payer
coverage, documentation, and compliance requirements.

Our
revenue will vary based on patient participation, service utilization, and the number of active patients enrolled by each practice.

Allergy
Diagnostics and Treatment (AllergiEnd®)

AllergiEnd®
is our allergy diagnostics and treatment offering, designed to enable primary care practices to identify and manage allergic disease
within the primary care setting. This service line operates in coordination with the QHSLab digital platform and reflects management’s
strategy of supporting chronic disease identification and management at the point of first contact with the healthcare system.

The
first point of contact for most patients experiencing allergy-related symptoms is their primary care physician or pediatrician. It is
estimated that approximately 60 million individuals in the United States are affected by allergic disorders. In contrast, there are fewer
than 3,000 practicing board-certified allergists and approximately 2,400 board-certified otolaryngologists with a specialization in allergy,
resulting in limited specialty capacity relative to patient demand. Workforce projections indicate a decline in the number of full-time
equivalent allergists over time, while demand for allergy-related services is expected to increase.

Historically,
the diagnosis and treatment of allergic diseases have remained largely within the specialist domain, despite the expansion of primary
care management into other chronic conditions. This has contributed to underdiagnosis and symptom-based treatment approaches for many
patients.

Integration
of Allergy Services with the Digital Platform

We
integrate allergy screening into our digital assessment workflows, enabling practices to identify patients with potential allergic diseases
at scale. Digital screening supports more efficient use of in-office diagnostic resources and assists practices in prioritizing patients
for further evaluation.

Following
digital screening, participating practices may utilize the AllergiEnd® system to perform in-office allergy skin testing. This workflow
is designed to allow primary care providers, physician assistants, nurse practitioners, and nursing staff to confirm allergen sensitivity
within the practice environment, subject to applicable clinical oversight and training.

This
integrated approach aligns with our broader strategy of combining population-based digital screening with targeted diagnostic confirmation
and follow-up care.

AllergiEnd®
Products and Services

The
AllergiEnd® product line consists primarily of FDA-cleared, disposable, single-use allergy skin test applicators and matching test
trays designed for office-based use. These devices enable testing for a broad range of common allergens and are intended to support standardized
and efficient testing workflows.

As
part of our service offering, we provide training and operational support to participating practices related to:

●
Digital allergy screening using the QHSLab platform

●
In-office allergy skin testing procedures

●
Interpretation of test results

●
Integration of allergy findings into patient care plans

We
do not manufacture allergen extracts. Allergen immunotherapy preparations are provided by third-party compounding pharmacies pursuant
to prescriptions issued by treating physicians.

4

Allergy
Treatment and Immunotherapy

Following
diagnostic confirmation, participating physicians may prescribe allergen immunotherapy tailored to the patient’s identified sensitivity.
Immunotherapy is designed to gradually desensitize patients to specific allergens through controlled exposure over time.

Treatment
may be administered through subcutaneous injections in the physician’s office or through sublingual oral drops administered by
patients at home, depending on the treatment plan prescribed by the physician. These treatment approaches are consistent with established
allergy treatment practices.

Target
Customers

Our
current target customers are independent, physician-led primary care practices, generally consisting of one to ten providers. These practices
typically:

●
Control their own clinical workflows

●
Bill Medicare, and/or commercial insurance

●
Manage diverse patient populations

●
Face operational and time constraints related to screening
and follow-up care

We
do not focus our sales efforts on large health systems, or hospital-owned practices.

Sales
and Implementation Approach

We
employ a focused, capital-efficient sales strategy designed to limit sales cycle duration and implementation risk. We primarily engage
prospective customers through existing relationships, referrals, and targeted direct sales and marketing activities.

Industry
Background

The
healthcare industry is shifting toward preventive care, population health management, and non-face-to-face clinical services. Primary
care practices face increasing pressure to identify and manage chronic conditions and behavioral health concerns within constrained visit
times and staffing resources. At the same time, reimbursement frameworks increasingly recognize digital assessments, asynchronous care,
and ongoing care management when appropriately documented. High-prevalence behavioral health needs—depression, anxiety, suicide
risk, and related psychosocial risk—are particularly well-suited to standardized “behavioral vital signs” workflows
that enable scalable screening, longitudinal monitoring, and population-level management.

Competition

We
compete with a range of healthcare technology and medical device providers, including:

●
Point-solution digital health vendors focused on single conditions

●
Behavioral health screening and care management platforms

●
Chronic care management software providers

●
EHR-embedded tools and third-party add-ons

●
Allergy diagnostic device manufacturers and specialty-focused
providers

Many
competitors have greater financial, technical, or marketing resources than our Company. Competition in both digital health and allergy
diagnostics markets is intense.

Growth
Strategy

Our
near-term growth strategy focuses on expanding adoption among independent primary care practices, increasing patient enrollment per practice,
and supporting recurring revenue growth through sustained patient engagement.

Longer-term
growth opportunities may include expansion into additional clinical domains, deeper workflow integration, and broader strategic partnerships,
subject to available capital and regulatory considerations.

Intellectual
Property

Although
certain of our current software applications and pioneering methods, as well as those developed in the future, will be eligible for patent
and trademark protection, we believe that the costs of maintaining and enforcing such intellectual property rights may not afford us
a competitive advantage and for the immediate future we intend to rely primarily on maintaining the secrecy of our proprietary information.

5

Regulatory
Considerations

Our
platform is designed to support clinical services provided by licensed healthcare professionals. We do not provide medical diagnoses
or treatment decisions and do not deliver medical care.

Participating
practices are responsible for compliance with applicable healthcare laws and regulations, including billing, documentation, privacy,
and professional practice standards. Our operations are subject to evolving regulatory requirements related to healthcare technology,
medical devices, data privacy, and reimbursement.

Government
Regulation

The
healthcare industry is heavily regulated and closely scrutinized by federal, state and local governments. Comprehensive statutes and
regulations govern the manner in which we and the PCPs which use our products provide and bill for services and collect reimbursement
from governmental programs and private payors, our contractual relationships with vendors and clients, our marketing activities and other
aspects of our operations. Of particular importance are:

●
the federal physician self-referral
law, commonly referred to as the Stark Law;

●
the federal Anti-Kickback
Act;

●
the criminal healthcare
fraud provisions of HIPAA;

●
the federal False Claims
Act;

●
reassignment of payment
rules that prohibit certain types of billing and collection by companies which do business with PCPs;

●
similar state law provisions
pertaining to anti-kickback, self-referral and false claims issues;

●
state laws that prohibit
general business corporations, such as us, from practicing medicine; and

●
laws that regulate debt
collection practices as applied to our debt collection practices.

Because
of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our
business activities could be subject to challenge under one or more of such laws. Dealing with investigations can be time- and resource-consuming
and can divert management’s attention from our business.

The
FDA issued a Finalized Guidance on medical mobile applications (“Apps”). The FDA determined that certain Apps may meet the
definition of a medical device because they provide the user with certain biologic information. The Guidance contains an appendix that
provides examples of mobile apps that may meet the definition of a medical device but for which the FDA intends to exercise enforcement
discretion. These mobile apps may be intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment,
or prevention of disease. Even though these mobile apps may meet the definition of a medical device, the FDA intends to exercise enforcement
discretion for these mobile apps because they pose lower risk to the public. Based on our understanding of the Guidance, although there
can be no guarantee, we believe our QHSLab services will eventually be subject to regulatory requirements because such services seem
to fall within the statutory examples of medical devices with respect to which the FDA intends to monitor compliance with applicable
regulations. Although many of the Apps described in the Guidance have been in use for an extended period of time, the impact they have
had on the need for patient visits to a physician and thus, on the use of our products, has not been determined.

Based
on our understanding of the Guidance, although there can be no guarantee, we believe our QHSLab services will eventually be subject to
regulatory requirements because such services seem to fall within the statutory examples of medical devices with respect to which the
FDA intends to monitor compliance with applicable regulations.

Employees

As
of March 30, 2026, we had twelve employees devoting full-time services to the Company, all of whom were engaged in direct sales and
operations. In addition, we engage independent entities and consultants that provide programming services, quality management system
development, marketing, business development and medical consulting and advisory services. We believe that our relationships with
our employees and consultants are good.

6